INFLUENCE OF INGARON ON THE DYNAMICS OF INTERFERON-α AND -γ PRODUCTION AND ON THE MANIFESTATION OF CLINICAL SYMPTOMS IN PATIENTS WITH CHRONIC VIRUS EРSTHTEIN-BARR INFECTION

Cover Page


Cite item

Full Text

Abstract

Introduction. Patients with chronic herpes virus infection develop impaired IFN-α and IFN-γ products due to secondary immunodeficiency, which leads to impaired elimination of the intracellular virus and the development of chronic recurrent infection. It has been shown that IFN-γ is a potent immunoregulatory cytokine and has an antiviral effect. The aim of the study is to study the effect of Ingaron therapy on the dynamics of IFN-α and IFN-γ production and the clinical picture in patients with chronic Epstein-Barr virus infection (ChEBVI). Material and methods. 32 patients with ChEBVI were examined. The average age of patients was 35.06 ± 1.60 years. There were 22 women, 10 men. Serum IFN-α and IFN-γ, spontaneous and induced cytokine production in blood lymphocyte cultures were determined. As an inducer of IFN-α products, the Newcastle disease virus was used (obtained in the LA Tarasevich State Medical Institute, St. Petersburg) with an infectious titer of 8 lg EID / 0.2 ml in a volume of 8 μl per well, as an inducer of IFN-γ products, phytohemagglutinin (PanEco, Russia) was used at a dose of 10 µg / ml. The quantitative content of cytokines was determined in the serum and supernatant of a 24-hour whole blood culture using enzyme-linked immunosorbent assay (ELISA) using test systems (Vector Best, Russia). Results. It was shown that the content of IFN-γ decreased (P = 0.013) after Ingaron therapy in patients with initially high levels of induced IFN-γ (4435.64 ± 1343.50 pg/ml). In patients with initially low levels of induced IFN-γ (234.25 ± 34 , 31 pg / ml) the content of IFN-γ increased (P = 0.002). Ingaron leads to an increase in spontaneous and serum IFN-γ production in patients. Conclusions. Conducting Ingaron therapy with ChEBVI is shown independently of the initial production of IFN-γ-induced lymphocyte culture. Ingaron is recommended for the treatment of patients with ChEBVI at a dose of 500,000 IU with a course dose of 10 or more injections.

About the authors

I. A. Rakityanskaya

Outpatient Department of Allergology-Immunology and Clinical Transfusiology City Ambulant Department №112

Author for correspondence.
Email: tat-akyla@inbox.ru
Russian Federation

T. S. Ryabova

Outpatient Department of Allergology-Immunology and Clinical Transfusiology City Ambulant Department №112; Military Medical Academy named after S.M. Kirov, St. Petersburg

Email: noemail@neicon.ru
Russian Federation

A. A. Kalashnikova

The Nikiforov Russian Center of Emergency and Radiation Medicine

Email: noemail@neicon.ru
Russian Federation

References

  1. Straus S.E. The chronic mononucleosis syndrome. J. Infect. Dis. 1988; 157(3): 405-12.
  2. Rickinson A.B. Chronic, symptomatic Epstein-Barr virus infection. Immunol. Today. 1986; 7(1): 13-4. doi: 10.1016/0167-5699(86)90183-0
  3. Hellmann D., Cowan M.J., Ammann A.J., Wara D.W., Chudwin D., Chang R.S. Chronic active Epstein-Barr virus infections in two immunodeficient patients. J. Pediatr. 1983; 103(4): 585-8.
  4. Joncas J.H., Ghibu F., Blagdon M., Montplaisir S., Stefanescu I., Menezes J. A familial syndrome of susceptibility to chronic active Epstein-Barr virus infection. Can. Med. Assoc. J. 1984; 130(3): 280-4.
  5. Hochberg D., Middeldorp J.M., Catalina M., Sullivan J.L., Luzuriaga K., Thorley-Lawson D.A. Demonstration of the Burkitt’s Lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc. Natl. Acad. Sci. USA. 2003; 101(1): 239-44.
  6. Niller H.H., Wolf H., Minarovits J. Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity. 2008; 41(4): 298-328.
  7. Kanegane H., Wakiguchi H., Kanegane C., Kurashige T., Tosato G. Viral interleukin-10 in chronic active Epstein-Barr virus infection. J. Infect. Dis. 1997; 176(1): 254-7.
  8. Amyes E., Hatton C., Montamat-Sicotte D., Gudgeon N., Rickinson A.B., McMichael A.J., et al. Characterization of the CD4+ T Cell Response to Epstein-Barr Virus during Primary and Persistent Infection. J. Exp. Med. 2003; 198(6): 903-11.
  9. Marrão G., Habib M., Paiva A., Bicout D., Fallecker C., Franco S., et al. Epstein-Barr virus infection and clinical outcome in breast cancer patients correlate with immune cell TNF-α/IFN-γ response. BMC Cancer. 2014; 14: 665. doi: 10.1186/1471-2407-14-665
  10. Cohen J.I. Epstein-Barr virus infection. N. Engl. J. Med. 2000; 343(7): 481-92.
  11. Kimura H., Hoshino Y., Kanegane H., Tsuge I., Okamura T., Kawa K., et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001; 98(2): 280-6.
  12. Ohga S., Nomura A., Takada H., Ihara K., Kawakami K., Yanai F., et al. Epstein-Barr virus (EBV) load and cytokine gene expression in activated T cells of chronic active EBV infection. J. Infect. Dis. 2001; 183(1): 1-7.
  13. Gattoni A., Parlato A., Vangieri B., Bresciani M., Derna R. Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts). Clin. Ter. 2006; 157(4): 377-86.
  14. Schroder K., Hertzog P.J., Ravasi T., Hume D.A. Interferon-gamma: an overview of signals, mechanisms and functions. J. Leukoc. Biol. 2004; 75(2): 163-89.
  15. Saha B., Jyothi Prasanna S., Chandrasekar B., Nandi D. Gene modulation and immunoregulatory roles of interferon gamma. Cytokine. 2010; 50(1): 1-14. doi: 10.1016/j.cyto.2009.11.021
  16. Johnson H.M., Noon-Song E.N., Dabelic R., Ahmed C.M. IFN signaling: how a non-canonical model led to the development of IFN mimetics. Front. Immunol. 2013; 4: 202. doi: 10.3389/fimmu.2013.00202
  17. Roff S.R., Noon-Song E.N., Yamamoto J.K. The Significance of Interferon-gamma in HIV-1 Pathogenesis, Therapy, and Prophylaxis. Front. Immunol. 2014; 4: 498. doi: 10.3389/fimmu.2013.00498
  18. Smith N.L., Denning D.W. Clinical implications of interferon-γ genetic and epigenetic variants. Immunology. 2014 Dec; 143(4): 499-511. doi: 10.1111/imm.12362
  19. Watford W.T., Moriguchi M., Morinobu A., O’Shea J.J. The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev. 2003; 14(5): 361-8.
  20. Robinson C.M., O’Dee D., Hamilton T., Nau G.J. Cytokines involved in interferon-γ production by human macrophages. J. Innate Immunol. 2010; 2(1): 56-65.doi: 10.1159/000247156
  21. Сологуб Т.В., Цветков В.В., Деева Э.Г. Интерферон гамма-цитокин с противовирусной, иммуномодулирующей и противоопухолевой активностью. Российский медико-биологический вестник имени академика И.П. Павлова. 2014; (3): 56-60
  22. Fujisaki T., Nagafuchi S., Okamura T. Gamma-interferon for severe chronic active Epstein-Barr virus. Ann. Intern. Med. 1993; 118(6): 474-5.
  23. Andersson J. Clinical and immunological considerations in Epstein-Barr virus-associated diseases. Scand. J. Infect. Dis. Suppl. 1996; 100: 72-82.
  24. Balachandra K., Thawaranantha D., Ayuthaya P.I., Bhumisawasdi J., Shiraki K., Yamanishi K. Effects of human alpha, beta and gamma interferons on varicella zoster virus in vitro. Southeast Asian J. Trop. Med. Public Health. 1994; 25(2): 252-7.
  25. Patterson C.E., Lawrence D.M., Echols L.A., Rall G.F. Immune-mediated protection from measles virus-induced central nervous system disease is noncytolytic and gamma interferon dependent. J. Virol. 2002; 76(9): 4497-506.
  26. Schultzn U., Chisari F.V. Recombinant duck interferon gamma inhibits duck hepatitis B virus replication in primary hepatocytes. J. Virol. 1999; 73(4): 3162-8.
  27. Laichalk L.L., Hochberg D., Babcock G.J., Freeman R.B., Thorley-Lawson D.A. The dispersal of mucosal memory B cells: evidence from persistent EBV infection. Immunity. 2002; 16(5): 745-54
  28. Kragsbjerg P. Chronic active mononucleosis. Scand. J. Infect. Dis. 1997; 29(5): 517-8.
  29. Гайнанова Е.Г., Фазылов В.Х., Скороходкина О.В. Клиническая эффективность цитокинотерапии гамма-интерфероном при варицелла-зостер герпесвирусной инфекции. Журнал инфектологии. 2010; 2(4): 56.
  30. Ершов Ф.И., Наровлянский А.Н., Чистик О.В., Халдин А.А., Орехов Д.В., Гетиа Т.Б. Гамма-Интерферон: новые возможности современной профилактики обострений простого герпеса. Российский журнал кожных и венерических болезней. Приложение «Герпес». 2009; (2): 11-3.
  31. Okano M., Thiele G.M., Kobayashi R.H., Davis J.R., Synovec M.S., Grierson H.L., et al. Interferon-gamma in a family with X-linked lymphoproliferative syndrome with acute Epstein-Barr virus infection. J. Clin. Immunol. 1989; 9(1): 48-54

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Rakityanskaya I.A., Ryabova T.S., Kalashnikova A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС77-77676 от 29.01.2020.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies